V
Vivo Capital, LLC
+ HoldingETNB
+15.70%
3M Return
$14.840
0.000 (0.00%)At close
Loading chart…
- High
- 14.870
- Open
- 14.830
- VWAP
- 14.84
- Vol
- 55.65M
- Mkt Cap
- 741.82M
- Low
- 14.820
- Amount
- 825.96M
- EV/EBITDA, TTM
- -2.85
89bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The Company’s lead product candidate, pegozafermin, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Pegozafermin is engineered to protect against proteolysis and reduce renal clearance and optimize its potency, enabling the potential use of a lower dosage/dose. Pegozafermin has been optimally constructed with two mutations via substitutions with natural amino acids at site-specific positions (173 and 176) toward the C-terminus end of the hormone.
Valuation Metrics
The current forward P/E ratio for 89Bio Inc (ETNB) is -3.58, compared to its 5-year average forward P/E of -4.14.
Whales holding ETNB
Events Timeline
News
4.010-31BenzingaCantor Fitzgerald Halts Overweight Rating for 89bio
7.010-16PRnewswireSHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates SWKH, ETNB, BRNS, VRNT on Behalf of Shareholders
7.010-16GlobenewswireBRODSKY & SMITH INVESTOR ALERT: Updates on Ongoing Investigations for 89bio, Inc. (Nasdaq - ETNB), Barinthus Biotherapeutics plc (Nasdaq - BRNS), Verint Systems Inc. (Nasdaq - VRNT), and Dayforce, Inc. (NYSE - DAY)
7.010-08GlobenewswireSHAREHOLDER RIGHTS NOTICE: Halper Sadeh LLC Probes DAY, BRNS, ETNB, VRNT for Shareholder Interests
7.010-08GlobenewswireBRODSKY & SMITH INVESTOR ALERT: Updates on Investigations Involving 89bio, Inc. (Nasdaq - ETNB), Barinthus Biotherapeutics plc (Nasdaq - BRNS), Verint Systems Inc. (Nasdaq - VRNT), and Dayforce, Inc. (NYSE - DAY)
ETNB FAQ — answered by Alphio AI
89bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The Company’s lead product candidate, pegozafermin, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Pegozafermin is engineered to protect against proteolysis and reduce renal clearance and optimize its potency, enabling the potential use of a lower dosage/dose. Pegozafermin has been optimally constructed with two mutations via substitutions with natural amino acids at site-specific positions (173 and 176) toward the C-terminus end of the hormone. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.